← Leaderboards
Kari N Nejak-Bowen
University Of Pittsburgh At Pittsburgh
$7,645,432
Attributed
$8,892,333
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,892,333 · 5
By mechanism
R01$8,426,202 · 3
P30$466,131 · 2
Top collaborators
- Satdarshan Singh Monga4 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Tirthadipa Pradhan-Sundd$736,235
- Karis Kosar$89,540
- Patrick James McKiernan$683,173
- Laura Maria Molina$101,556
- Jacquelyn Olivia Russell$229,428
Others in their field
Top investigators on “Liver”
- David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard Douglas Moore · Johns Hopkins University$59,048,354
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- Mark A Kay · Stanford University$49,905,067
Research focus
LiverInjuryKnockout MiceMedicalFibrosisBeta CateninPathway InteractionsMouse ModelPhenotypeRegulationHepatocyteSignal TransductionPathologyBaseCholestasisKnock-OutDefectDietIn VitroBile DuctChronicEtiologyDisease ProgressionLife
Grant awards (26)
Role and regulation of beta-catenin in cholestatic liver disease$596,342
R01 · FY2025 · DK · contact PI
Enrichment Program$90,698
P30 · FY2025 · DK · contact PI
Role and regulation of beta-catenin in cholestatic liver disease$615,393
R01 · FY2024 · DK · contact PI
Beta-catenin inhibition as a novel therapeutic strategy for porphyria$420,545
R01 · FY2024 · DK · contact PI
Enrichment Program$90,698
P30 · FY2024 · DK · contact PI
Role and regulation of beta-catenin in cholestatic liver disease$641,034
R01 · FY2023 · DK · contact PI
Beta-catenin inhibition as a novel therapeutic strategy for porphyria$438,067
R01 · FY2023 · DK · contact PI
Beta-catenin-driven hepatobiliary reprogramming as a therapeutic modality for cholangiopathies$400,869
R01 · FY2023 · DK · contact PI
Enrichment$36,849
P30 · FY2023 · DK · contact PI
Role and regulation of beta-catenin in cholestatic liver disease$641,034
R01 · FY2022 · DK · contact PI
Beta-catenin inhibition as a novel therapeutic strategy for porphyria$438,067
R01 · FY2022 · DK · contact PI
Beta-catenin-driven hepatobiliary reprogramming as a therapeutic modality for cholangiopathies$400,869
R01 · FY2022 · DK · contact PI
Enrichment$49,889
P30 · FY2022 · DK · contact PI
Beta-catenin inhibition as a novel therapeutic strategy for porphyria$435,210
R01 · FY2021 · DK · contact PI
Beta-catenin-driven hepatobiliary reprogramming as a therapeutic modality for cholangiopathies$400,869
R01 · FY2021 · DK · contact PI
Enrichment$36,849
P30 · FY2021 · DK · contact PI
Beta-catenin inhibition as a novel therapeutic strategy for porphyria$462,077
R01 · FY2020 · DK · contact PI
Beta-catenin-driven hepatobiliary reprogramming as a therapeutic modality for cholangiopathies$400,869
R01 · FY2020 · DK · contact PI
Enrichment$78,065
P30 · FY2020 · DK · contact PI
Beta-catenin-driven hepatobiliary reprogramming as a therapeutic modality for cholangiopathies$402,457
R01 · FY2019 · DK · contact PI
Role and regulation of beta-catenin in cholestatic liver disease$346,500
R01 · FY2019 · DK · contact PI
Enrichment$83,083
P30 · FY2019 · DK · contact PI
Role and regulation of beta-catenin in cholestatic liver disease$346,500
R01 · FY2018 · DK · contact PI
Role and regulation of beta-catenin in cholestatic liver disease$346,500
R01 · FY2017 · DK · contact PI
Role and regulation of beta-catenin in cholestatic liver disease$346,500
R01 · FY2016 · DK · contact PI
Role and regulation of beta-catenin in cholestatic liver disease$346,500
R01 · FY2015 · DK · contact PI